Abstract TP83: Sulfonylurea Pretreatment Does Not Impact Acute Ischemic Stroke Outcomes Following Intravenous Thrombolysis

    loading  Checking for direct PDF access through Ovid

Abstract

Background&Purpose: Experimental and retrospective clinical data have indicated that sulfonylurea drugs (SUD) may confer protection against cerebral swelling and hemorrhagic transformation in AIS. We sought to determine whether pretreatment and in-hospital use of SUD may be associated with better outcomes in diabetic AIS patients treated with IVT.

Subjects&Methods: We retrospectively analyzed prospectively collected data of consecutive AIS treated with IVT during a three-year period. Pre-treatment NIHSS, NIHSS at 48 hours and modified Rankin Scale (mRS) at discharge were documented. Symptomatic intracerebral hemorrhage (sICH) was defined as imaging evidence of ICH with NIHSS increase of 4 points within 72 hours. Early neurological improvement was defined as a NIHSS-score decrease of ≥4 points or a NIHSS-score of 0 at 48 hours. Cerebral edema was documented by neuroradiology reports. Favorable functional outcome (FFO) was defined as mRS of 0-1.

Results: A total of 148 diabetic AIS patients fulfilled the study inclusion criteria (mean age 64±11 years, 49% men, median admission NIHSS-score: 8 points). We identified 42 patients pre-treated with SUD (mean age 65±11 years, 50% men, median admission NIHSS-score: 8 points) all of whom continued to receive these medications during hospitalization. Demographic characteristics, vascular risk factors and admission NIHSS-scores did not differ (p>0.1) between patients pretreated (cases) and non-pretreated with SUD (controls). The prevalence of complications and favorable outcomes did not differ (p>0.1) between cases and controls: sICH (2% vs. 5%), cerebral edema (5% vs 4%), early neurological improvement (42% vs 43%), in-hospital mortality (12% vs 5%) and FFO (22% vs 32%).

Conclusions: Pretreatment and in-hospital use of SUD appears not to be associated with early favorable outcomes and lower likelihood of potential complications in diabetic AIS patients treated with IVT.

Related Topics

    loading  Loading Related Articles